AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00294515
Drug: Valganciclovir
RxNorm normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 900 mg orally daily for up to 200 days
Trial: NCT00645866
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00645866
Drug: epirubicin hydrochloride
RxNorm normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01156363
Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once monthly, subcutaneously or intravenously, for 32 weeks
Trial: NCT03561831
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: propofol based anesthesia
Trial: NCT03561831
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sevoflurane based anesthesia
Trial: NCT01838538
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01838538
Drug: TC:paclitaxel + carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01478529
Drug: mirabegron OCAS
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT01478529
Drug: mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iv administration
Trial: NCT00568035
Drug: QR-333
RxNorm normalized name: QR-333
DrugBank: QR-333 (DB05533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QR-333 or placebo will be applied three times a day for 12 weeks
Trial: NCT03062150
Drug: Fludrocortisone
RxNorm normalized name: Fludrocortisone
DrugBank: Fludrocortisone (DB00687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludrocortisone
Trial: NCT03062150
Drug: D-Cycloserine
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-Cycloserine
Trial: NCT03415087
Drug: hyperbaric bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intrathecal injection of intrathecal bupivacaine
Trial: NCT00662506
Drug: Cediranib Maleate
RxNorm normalized name: maleate
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04305236
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04305236
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given Intramuscularly
Trial: NCT03785340
Drug: Brimonidine Tartrate
RxNorm normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine Tartrate Nanoemulsion Eye Drops 0.20% given 2 times a day for 4 weeks.
Trial: NCT00043095
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00662506
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00043095
Drug: ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02684851
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid: anti-fibrinolytic agents
Trial: NCT01240187
Drug: perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose of 6 tablets 2 mg orally
Trial: NCT01240187
Drug: perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose of 1 tablet 12 mg orally
Trial: NCT01578200
Drug: Lanthanum Carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01578200
Drug: Calcium Carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01303029
Drug: Gemcitabine+erlotinib
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .
Trial: NCT02555852
Drug: esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exposure to esomeprazole (ATC A02BC05, B01AC56, M01AE52, A02BD06) will be defined as a prescription for esomeprazole on the same day as a ≥ 30 day NSAID prescription.
Trial: NCT02555852
Drug: omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exposure to omeprazole (ATC A02BC01, A02BD01) will be defined as a prescription for omeprazole on the same day as a ≥ 30 day NSAID prescription.
Trial: NCT02555852
Drug: pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exposure to pantoprazole (ATC A02BC02, A02BD04) will be defined as a prescription for pantoprazole on the same day as a ≥ 30 day NSAID prescription.
Trial: NCT02555852
Drug: lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exposure to lansoprazole (ATC A02BC03, A02BD07, A02BD03, A02BD02) will be defined as a prescription for lansoprazole on the same day as a ≥ 30 day NSAID prescription.
Trial: NCT02555852
Drug: rabeprazole
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exposure to rabeprazole (ATC A02BC04) will be defined as a prescription for rabeprazole on the same day as a ≥ 30 day NSAID prescription.
Trial: NCT02555852
Drug: cimetidine
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exposure to cimetidine (ATC A02BA01) will be defined as a prescription for cimetidine on the same day as a ≥ 30 day NSAID prescription.
Trial: NCT02555852
Drug: ranitidine
RxNorm normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exposure to ranitidine (A02BA02) will be defined as a prescription for ranitidine on the same day as a ≥ 30 day NSAID prescription.
Trial: NCT02555852
Drug: famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exposure to famotidine (A02BA03) will be defined as a prescription for famotidine on the same day as a ≥30 day NSAID prescription.
Trial: NCT02555852
Drug: nizatidine
RxNorm normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exposure to nizatidine (A02BA04) will be defined as a prescription for nizatidine on the same day as a ≥ 30 day NSAID prescription.
Trial: NCT02555852
Drug: niperotidine
RxNorm normalized name: niperotidine
DrugBank: Niperotidine (DB13760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to niperotidine (A02BA05) will be defined as a prescription for niperotidine on the same day as a ≥ 30 day NSAID prescription.
Trial: NCT02555852
Drug: ranitidine bismuth citrate
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exposure to ranitidine bismuth citrate (A02BA07) will be defined as a prescription for ranitidine bismuth citrate on the same day as a ≥ 30 day NSAID prescription.
Trial: NCT02555852
Drug: cimetidine combinations
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exposure to cimetidine combinations (A02BA51) will be defined as a prescription for cimetidine combinations on the same day as a ≥ 30 day NSAID prescription.
Trial: NCT02555852
Drug: famotidine combinations
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exposure to famotidine combinations (A02BA53) will be defined as a prescription for famotidine combinations on the same day as a ≥ 30 day NSAID prescription.
Trial: NCT01489891
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Applying of 5 puff controlled released (50 mg) transoral spray of lidocaine (10 mg=1 puff).
Trial: NCT03415152
Drug: Omacor (Omega-3-acid ethyl esters)
RxNorm normalized name: Omega-3-Acid Ethyl Esters
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observational study without intervention, Omacor is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.
Trial: NCT00574613
Drug: P144
RxNorm normalized name: Pimavanserin
DrugBank: Pimavanserin (DB05316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cream 0,3 ml once a day (3 months)
Trial: NCT03364491
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of Tranexamic Acid (1 gram) in normal saline for a total of 50cc, administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)
Trial: NCT02832778
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz 400mg
Trial: NCT02832778
Drug: tenofovir /emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tenofovir 245 mg/emtricitabine 200mg
Trial: NCT02832778
Drug: tenofovir/lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tenofovir 245mg/lamivudine 300mg
Trial: NCT02832778
Drug: lamivudine/zidovudine
RxNorm normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lamivudine 300mg/zidovudine 600mg
Trial: NCT00281944
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00946647
Drug: Panobinostat (LBH589)
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panobinostat was supplied by Novartis as immediate-release hard gelatin capsules in strengths of 5 mg, 10 mg, and 20 mg packaged in high density polyethylene bottles.
Trial: NCT00946647
Drug: 5-Azacytidine
RxNorm normalized name: 5-azacytidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00615433
Drug: Lurasidone
RxNorm normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 120mg/day
Trial: NCT00615433
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15mg/day
Trial: NCT00615433
Drug: Lurasidone 40 mg tablets
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lurasidone 40 mg tablets
Trial: NCT04602273
Drug: Azacitidine Injection [Vidaza]
RxNorm normalized name: azacitidine Injection [Vidaza]
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02211885
Drug: 14C-BIRB 796 BS
RxNorm normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14C-radiolabeled BIRB 796 BS
Trial: NCT01337583
Drug: Dapivirine
RxNorm normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00623402
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2x 400 mg orally per day (4 tablets)
Trial: NCT00623402
Drug: pegylated interferon α-2b
RxNorm normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3 µg/kg body weight s.c. once a week
Trial: NCT00185367
Drug: SH D 593 B (Miranova)
RxNorm normalized name: Glutathione-SH
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 cycles each consisting of 28 days (no tablet-free intervals); Day 1-21: 0.02 mg EE + 0.10 mg LNG; Day 22-28: placebo; In addition EV/DNG (Qlaira, BAY86-5027, SH T00658K) matching placebo
Trial: NCT06193304
Drug: Eliglustat
RxNorm normalized name: Eliglustat
DrugBank: Eliglustat (DB09039)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form:solution -Route of administration: Oral wihtout ingestion
Trial: NCT00956059
Drug: prednisone, FK506, MMF
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.in the initial 3 months，prednisone dosage is 30mg per day；in the following 4\~6 months，prednisone dose decreased to 20mg per day，then tapered gradually to 10mg per day；2.the initial dosage of FK506 is 0.2mg/kg/d, twice per day，the maintenance dosage is adjust to the serum concentration of FK506 (is maintained at the level of 6\~10μg/L)；3. the initial dosage of MMF is 1.0g, twice per day，then reduce to 0.75 g, twice per day after 3 months
Trial: NCT00956059
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the initial 16\~24 weeks，prednisone is given at full dose of 1mg/kg/d，then prednisone is tapered gradually，the whole course of treatment is 52 weeks
Trial: NCT01853644
Drug: Tivozanib
RxNorm normalized name: Tivozanib
DrugBank: Tivozanib (DB11800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1.5 mg Given PO (orally)days 1-21 or every 28 day cycle
Trial: NCT00255567
Drug: Sodium Stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Stibogluconate 20mg/kg/day for 30 days
Trial: NCT02891408
Drug: Firsocostat
RxNorm normalized name: Firsocostat
DrugBank: Firsocostat (DB16166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule(s) administered orally on Day 1
Trial: NCT02891408
Drug: Fenofibrate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet administered orally on Day 1
Trial: NCT04621318
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 60 mg, single-dose
Trial: NCT02519400
Drug: Amitriptyline
RxNorm normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dosing
Trial: NCT00493298
Drug: Tysabri
RxNorm normalized name: Tysabri
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: According to the local prescribing information
Trial: NCT03095001
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 5mg/kg intraperitoneal administration every 3 weeks for 4-6 cycles
Trial: NCT03095001
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: carboplatin AUC=5 intraperitoneal administration every 3 weeks 4-6 cycles
Trial: NCT03095001
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel 175mg/m2, iv d1, every 3 weeks for 4-6 cycles
Trial: NCT03713645
Drug: Tacrolimus Extended Release Oral Tablet [Envarsus] 0.13mg/kg/day initiated within post-operative day 3 after kidney transplant
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study drug (tacrolimus extended-release) initiated at 0.13/mg/kg/day for all patients
Trial: NCT01021215
Drug: Zileuton
RxNorm normalized name: Zileuton
DrugBank: Zileuton (DB00744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1200 mg twice daily given orally (PO) for 6 days
Trial: NCT02689518
Drug: Intravitreal aflibercept injection
RxNorm normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal aflibercept injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks(2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months.
Trial: NCT04997967
Drug: Ketamine/Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The level of sedation was assessed at 1-3 min intervals, and the infusion rate was adjusted accordingly to achieve a Ramsay Sedation Scale (RSS) score of 5. Any movement of the patient was treated by increasing infusion rate and the infusion was discontinued at the end of the procedure. The total propofol consumed was calculated and the recovery time was recorded and calculated as the time from discontinuation of infusion of the study drug till achievement of RSS score of 3. Then patients were discharged to post-anesthesia care unit (PACU) after attaining an Aldrete Recovery Scale Score of 9- 10 \[19\]. Time taken to achieve this score was also recorded.
Trial: NCT04997967
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sedation was initially started by bolus dose of 0.5 mg/kg propofol IV over 3 minutes then, infusion was started at the rate of 50 µg /kg/min till RSS score of 5.
Trial: NCT03402815
Drug: Maraviroc 300 mg
RxNorm normalized name: maraviroc 300 MG
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients were randomly allocated with an AB/BA cross over design to either maraviroc 300 mg/day to current ART for 24 weeks (A) or no additional treatment (B). At the end of the first 24-week period patients were switched to the alternative arm.
Trial: NCT02321072
Drug: Oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02592408
Drug: ASP
RxNorm normalized name: Asp
DrugBank: Aspartic acid (DB00128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 days of artesunate sulfadoxine/pyrimethamine on days 0-2
Trial: NCT02592408
Drug: SDPQ
RxNorm normalized name: Sulfadoxine and Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose primaquine on day 2
Trial: NCT02592408
Drug: 14DPQ
RxNorm normalized name: Fourteendeoxypaclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 14 day primaquine starting on day 2
Trial: NCT00622258
Drug: Everolmus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02753530
Drug: Arimoclomol
RxNorm normalized name: arimoclomol
DrugBank: Arimoclomol (DB05025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime
Trial: NCT01920854
Drug: soluble ferric pyrophosphate
DrugBank: Ferric pyrophosphate (DB09147)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03463161
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab (200mg/kg) given by intravenous infusion every 3 weeks.
Trial: NCT03463161
Drug: Epacadostat
RxNorm normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epacadostat (100mg) taken by mouth twice a day.
Trial: NCT01797796
Drug: PF-06305591
RxNorm normalized name: PF-06305591
DrugBank: PF-06305591 (DB12106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg PF 06305591 will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
Trial: NCT02696226
Drug: SAVR Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (81 mg/day) to begin within 1-3 postoperative days according to the patient's clinical status and continue indefinitely per standard of care.
Trial: NCT02696226
Drug: TAVR Aspirin and clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Aspirin (81 mg/day) and clopidogrel (75 mg/day) in periprocedural period and continue for 24 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
Trial: NCT00591357
Drug: loperamide
RxNorm normalized name: Loperamide
DrugBank: Loperamide (DB00836)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
Trial: NCT03745261
Drug: Salbutamol (Ventolin®)
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: According to the revised 2017 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salbutamol will be used to Group A patients: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose. 100 μg each time (when needed), and the maximum dose is 8-12 inhalations a day.
Trial: NCT03745261
Drug: Tiotropium Bromide (Spiriva®)
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiotropium Bromide Powder for Inhalation will be used to Group B and Group C patients: Tiotropium Bromide Powder for Inhalation(Spiriva®, Boehringer Ingelheim), 18μg/ capsule, 10 capsules. 18μg each time, once daily.